AlphAIAlphAI — Financial news for AI agents
quiverquant.comOCT 132 min read$JNJ

JOHNSON & JOHNSON ($JNJ) Releases Q3 2026 Earnings

Johnson & Johnson ($JNJ) reported Q3 2026 earnings of $2.59 per share, meeting estimates, with revenue of $25.4B, missing estimates by $179M. Insiders sold shares, while hedge funds increased positions. Analysts' price targets range from $265 to $298.

Original reporting
quiverquant.com
Published Oct 13, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
JOHNSON & JOHNSON ($JNJ) Releases Q3 2026 Earnings — source image
Source · quiverquant.com
Decision brief

The 30-second read

$JNJNeutralMed
01

Why it matters

The earnings miss may trigger short‑term selling pressure, but the stable EPS and dividend yield could provide support for long‑term holders.

02

Market read

First‑report earnings for a large‑cap health care stock; relevant for traders monitoring earnings-driven moves.

03

What to watch

Insider sales and hedge fund outflows may signal deeper concerns beyond the earnings numbers.

Relevance 8/10Novelty 8/10Timing: today

Background

The article is an earnings release summary from Quiver Quantitative, providing raw financial results and ancillary data such as insider trades and institutional holdings.

Company-level read

Ticker impact

$JNJNeutralHigh confidence
Context

Johnson & Johnson reported Q3 2026 earnings of $2.59 EPS (meeting estimates) and revenue of $25.4B (missing estimates).

Expected impact

likely modest downside pressure as revenue shortfall outweighs EPS beat

Evidence & confidence

Large‑cap earnings release with revenue below consensus typically drags price, while EPS in line provides limited support.

Market effects

Sector

Healthcare sector may see slight pullback as a major pharma player missed revenue expectations.

Regional

U.S. market may experience modest weakness in defensive stocks.

Global

Limited global impact; JNJ is a multinational but the earnings miss is U.S.-centric.

Counterpoint

What could challenge this read

Despite revenue miss, strong cash flow and dividend yield could attract income investors.

Key entities

  • company
    Johnson & Johnson

    U.S. healthcare conglomerate reporting Q3 2026 results.

Read at source← All news

StoryJohnson & Johnson posts Q3 2026 earnings, raises full‑year sales and EPS outlook despite one‑time charge

Also covered by

5 outlets

Related articles

OCT 13
$JNJHighAI 9/10

What Johnson & Johnson (JNJ) Said on Its Q3 Earnings Call

Johnson & Johnson (JNJ) reported Q3 sales growth across multiple drugs, including DARZALEX, CARVYKTI, and TECVAYLI. MedTech sales rose 2.5%, missing internal expectations. The company raised its full-year operational sales guidance to 6.7%-7.1% and expects $100.7B in operational sales. JNJ also announced a $5.5B proposed resolution for ovarian talc litigation and plans to spin off DePuy Synthes by mid-2027.

finance.yahoo.com7 min
OCT 13
$JNJMedAI 8/10

Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

Johnson & Johnson (JNJ) stock fell 5% despite raising its full-year outlook due to one-time charges, including talc litigation. Q3 2026 revenue grew 5.9%, but reported net earnings dropped 95.9%. Eli Lilly (LLY) and Pfizer (PFE) also saw declines. JNJ's growth came from its Innovative Medicine division, while MedTech lagged. The company secured market authorization for its OTTAVA robotic surgical system and priority review for RYBREVANT FASPRO.

247wallst.com7 min
OCT 13
$JNJHighAI 8/10

Tremfya rescues J&J’s immunology sales to fuel strong Q3

Johnson & Johnson reported Q3 sales of $25.4bn, beating estimates. Tremfya's sales surged 68.3% to $2.4bn, driving a 7.9% increase in the pharma segment. Overall immunology sales grew 1.3%, offset by declines in Stelara, Remicade, and Simponi. J&J raised its 2026 sales and EPS guidance, despite lower Q3 EPS due to acquisitions and legal settlements. Medtech sales grew 2.5%, led by Shockwave's 16.8% increase.

finance.yahoo.com2 min
OCT 13
$JNJMedAI 8/10

Johnson & Johnson raises 2026 guidance as quarterly sales climb

Johnson & Johnson (JNJ) raised its 2026 sales and earnings forecasts after Q3 sales grew 6%. Full-year sales midpoint increased to $101.2B, and adjusted EPS midpoint rose by $0.06 to $11.10. Q3 sales reached $25.4B, with adjusted EPS at $2.59. Growth was driven by Innovative Medicine and MedTech divisions, while Stelara sales declined. Shares fell over 5% on the news.

finance.yahoo.com2 min